Odonate Therapeutics is a pharmaceutical company focused on the development of therapeutics for patients with cancer. Co.'s initial focus is on the development of tesetaxel, an investigational, orally administered chemotherapy agent that belongs to a class of drugs known as taxanes, which are used in the treatment of cancer. Tesetaxel has several pharmacologic properties, including: oral administration with a low pill burden; a long terminal plasma half-life in humans, enabling the maintenance of adequate drug levels with relatively infrequent dosing; no history of hypersensitivity (allergic) reactions; and activity against chemotherapy-resistant tumors. The ODT stock yearly return is shown above.
The yearly return on the ODT stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2020 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ODT annual return calculation with any dividends reinvested as applicable (on ex-dates).
|